KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $101.8 million.

  • Vertex Pharmaceuticals' Capital Expenditures rose 5036.93% to $101.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $380.8 million, marking a year-over-year increase of 4468.09%. This contributed to the annual value of $297.7 million for FY2024, which is 4855.29% up from last year.
  • According to the latest figures from Q3 2025, Vertex Pharmaceuticals' Capital Expenditures is $101.8 million, which was up 5036.93% from $145.7 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Capital Expenditures ranged from a high of $145.7 million in Q2 2025 and a low of $33.6 million during Q4 2022
  • Its 5-year average for Capital Expenditures is $64.5 million, with a median of $59.6 million in 2023.
  • Examining YoY changes over the last 5 years, Vertex Pharmaceuticals' Capital Expenditures showed a top increase of 26452.44% in 2021 and a maximum decrease of 7002.2% in 2021.
  • Over the past 5 years, Vertex Pharmaceuticals' Capital Expenditures (Quarter) stood at $61.8 million in 2021, then crashed by 45.63% to $33.6 million in 2022, then skyrocketed by 72.92% to $58.1 million in 2023, then surged by 59.38% to $92.6 million in 2024, then rose by 9.94% to $101.8 million in 2025.
  • Its last three reported values are $101.8 million in Q3 2025, $145.7 million for Q2 2025, and $40.7 million during Q1 2025.